Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > Fc gamma RIIA / CD32a > SCCHO-ATP061H

CHO/Human CD32a Stable Cell Line (High Expression) Development Service

Order Now

  • Description
    The CHO/Human CD32a Stable Cell Line was engineered to express full length human CD32a receptor (Gene ID: 2212), with different levels of CD32a expression (High, Medium, Low), which can be used to test agonist antibody whether in a CD32a-dependent manner to strengthen the agonistic activity. When co-cultured with Human 4-1BB HEK293 Reporter Cell and anti-4-1BB agonist antibody, the anti-4-1BB antibody can be crosslinked, thereby strengthening 4-1BB pathway-activated luminescence.
  • Application

    • Useful for cell-based CD32a binding assay

    • Useful for CD32a-mediated crosslinking

     Fc gamma RIIA / CD32a Assay Principles

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin (20 μg/mL)
  • Culture Medium
    F-12K+ 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 Fc gamma RIIA / CD32a FACS

Expression analysis of human CD32a on CHO/Human CD32a Stable Cell Line (High Expression) by FACS.  
Cell surface staining using PE-labeled anti-human CD32a antibody was performed on CHO/Human CD32a Stable Cell Line with different expression levels: CHO/Human CD32a Stable Cell Line (Low Expression); CHO/Human CD32a Stable Cell Line (Medium Expression); CHO/Human CD32a Stable Cell Line (High Expression).

  • Background
    Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized. There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIM­bearing receptors may also be coexpressed and co­engaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B, and the strength of the signal is dependent on the ratio of expression of the activating and inhibitory receptors.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $3500.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:2 Details
  • Latest Research Phase:Phase 1 Clinical

Datasheet & Documentation

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message